NEW YORK — Scott Gottlieb, the commissioner of the Food and Drug Administration, is a free-market proponent in a fervently anti-regulatory administration who is trying to lower drug prices by expanding the regulatory reach of the agency.
Speaking Wednesday at CNBC’s Healthy Returns conference, Gottlieb criticized branded drug companies, distributors, and pharmacy benefit managers for practices that reduce competition and restrict market access to generic drugs, including biosimilars.
About the Author Reprints
